14C-radiolabeled (radiocarbon) drug studies are central to defining the disposition of therapeutics in clinical development. Concerns over radiation, however, have dissuaded investigators from conducting these studies as often as their utility may merit. Accelerator mass spectrometry (AMS), originally designed for carbon dating and geochronology, has changed the outlook for in-human radiolabeled testing.
Explore related content and topics
Blog
5 Tips for Healthy Social Distancing
Social distancing is a new term for us all—and now we hear it every day. According to PRA’s Dr. Greg Licholai, Chief Medical Information Officer,…
White Paper
Multi-Stakeholder Collaborations Can Minimize Barriers & Drive Rare Disease Clinical Programs to Better Patient Outcomes
Conducting clinical trials in rare diseases and advancing research pipelines requires a collaborative, multi-stakeholder approach. This process…
Page
Join PRA in China
The expertise of a global CRO + local know-how to deliver the highest caliber of clinical development services around the world.